ライフサイエンスコーパス: receptor subtype

1 ation is primarily through the adenosine A2a receptor subtype.

2 ols to evaluate the functional roles of this receptor subtype.

3 thought to be devoid of activity at the S1P2 receptor subtype.

4 (Delta-41 +/- 7%) via activation of the V1a receptor subtype.

5 oscillations in both species via the 5-HT1A receptor subtype.

6 amine binding to the allosteric site at this receptor subtype.

7 his arises from activation of the AT1 Ang II receptor subtype.

8 urosteroid-sensitive alpha4/delta containing receptor subtype.

9 that were distinct from either diheteromeric receptor subtype.

10 e selectivity and/or affinity for a specific receptor subtype.

11 tochastic activation of different macrophage receptor subtypes.

12 lining the intramembranous pocket in the two receptor subtypes.

13 diate antinociception through the A1 and A2A receptor subtypes.

14 set of approximately 400 different olfactory receptor subtypes.

15 llosteric ligands now available for all mGlu receptor subtypes.

16 ility to distinguish between closely related receptor subtypes.

17 binding pocket at any of the five muscarinic receptor subtypes.

18 iological actions of NPY are assigned to NPY receptor subtypes.

19 tly stimulating internalization of the three receptor subtypes.

20 have little or no effect on other muscarinic receptor subtypes.

21 s highly potent antagonists of GluA2-lacking receptor subtypes.

22 y due to nonspecific actions on various 5-HT receptor subtypes.

23 e observed at the different recombinant NMDA receptor subtypes.

24 prised of residues that are conserved in all receptor subtypes.

25 the function and physiological roles of NMDA receptor subtypes.

26 gion of the brain involving two different DA receptor subtypes.

27 amics and expression of ionotropic glutamate receptor subtypes.

28 vation of GluN1/GluN2A and GluN1/GluN2D NMDA receptor subtypes.

29 with a differential activation of glutamate receptor subtypes.

30 nces in agonist efficacy at recombinant NMDA receptor subtypes.

31 m constant at -100 mV is comparable for both receptor subtypes.

32 havior via activation of multiple adrenergic receptor subtypes.

33 ticularly in the presence of other adenosine receptor subtypes.

34 non-visual arrestins specific for particular receptor subtypes.

35 is >650-fold selective over other adenosine receptor subtypes.

36 vestigated the GABA binding sites of the two receptor subtypes.

37 gatively charged binding pocket in both NPFF receptor subtypes.

38 and pathological responses of the individual receptor subtypes.

39 lectivity over the related 5-HT2A and 5-HT2B receptor subtypes.

40 ionship and defining them as pharmacological receptor subtypes.

41 eric site is in the micromolar range for all receptor subtypes.

42 ns on different native and recombinant GABAA receptor subtypes.

43 unlike other FGF peptides, activates all FGF receptor subtypes.

44 electivity for either the kappa or the delta receptors subtypes.

45 showed enrichment of genes within histamine receptor (subtypes 1 and 2) signaling pathways (p = 5.8

46 ype 4 (M4) to oppose cAMP-dependent dopamine receptor subtype 1 (D1) signaling in presynaptic termina

47 tdTomato driven by the promoter for dopamine receptor subtype 1 (D1).

48 nhancement by blocking or ablating of PGE(2) receptor subtype 1 (EP1), approximately 30% enhancement

49 that corresponded with the engagement of S1P receptor subtype 1 (S1PR(1))- dependent neuroinflammator

50 the preparation of muscarinic acetylcholine receptor subtype 1 positive allosteric modulators.

51 s the role of corticotropin releasing factor receptor subtypes 1 and 2 (CRFR1, CRFR2) within the vent

52 oral agonist of the sphingosine-1-phosphate receptor subtypes 1 and 5 that induces peripheral lympho

53 nd functional activities toward melanocortin receptor subtypes 1, 3, 4, and 5 (hMCRs).

54 llosteric ligands for metabotropic glutamate receptor subtypes 1-5 and 7 (mGlu1-5,7) highlighting key

55 acid (1b), for cloned homomeric kainic acid receptors subtype 1 (GluK1) was attained (Ki = 4 muM).

56 ductance via the growth hormone secretagogue receptor subtype 1a-Galphai -PI3K-Erk1/2-KATP pathway.

57 ross-linking strategy to map the cannabinoid receptor subtype 2 (CB2)-Galphai interface and then used

58 The activation of cannabinoid receptor subtype 2 (CB2R) prevents acinar cell pathogene

59 y mouse microglia that lack prostaglandin E2 receptor subtype 2 (EP2) show decreased innate immune-me

60 pronounced deficit in metabotropic glutamate receptor subtype 2 (mGluR(2)).

61 n 12.6 (FKBP12.6), is a subunit of ryanodine receptor subtype 2 (RyR2) macromolecular complex, which

62 and survival via the sphingosine 1-phosphate receptor subtype 2 (S1P2) followed by an inhibition of A

63 vitro and in vivo evidence that somatostatin receptor subtype 2 (sst2) antagonists are better tools t

64 Somatostatin receptor subtype 2 (sstr2) is a G-protein-coupled recept

65 with picomolar affinity for the somatostatin receptor subtype 2 (SSTR2) upregulated in some pancreati

66 n for drugs that upregulate the somatostatin receptor subtype 2 (sstr2).

67 The somatostatin receptor subtype 2 is expressed on macrophages, an abund

68 AMBF3-TATE bound the somatostatin receptor subtype 2 with high affinity (inhibition consta

69 ctedly high binding affinity to somatostatin receptor subtype 2, and showed excellent pharmacokinetic

70 Visualization of somatostatin receptor subtype 2, for oncologic purposes, is frequentl

71 hat binds with high affinity to somatostatin receptor subtype 2, found on many human cancers, most cl

72 d (64)Cu and tested in vitro in somatostatin receptor subtype 2-overexpressing HEK-293 cells to asses

73 highest affinity yet found for somatostatin receptor subtype 2.

74 The serotonin receptor subtypes 2 comprise 5-HT2A, 5-HT2B, and 5-HT2C,

75 a-DOTANOC has high affinity for somatostatin receptor subtypes 2, 3, and 5 (sst2,3,5).

76 otid plaques were retrieved for somatostatin receptor subtype-2 (sst2) immunohistochemical staining.

77 d DOTATATE ((68)Ga-DOTATATE), a somatostatin receptor subtype-2 (SST2)-binding PET tracer, for imagin

78 (Cmpd-1), a novel A2AR/N-methyl d-aspartate receptor subtype 2B (NR2B) dual antagonist and potential

79 presynaptic group II metabotropic glutamate receptor subtype 3 (mGluR3) and suppresses glutamate rel

80 ocarcinoma cell lines abundantly express S1P receptor subtype 3 (S1P3), thus providing a tractable in

81 The somatostatin receptor subtype 3 (Sstr3) is selectively targeted to pr

82 with PV toward the muscarinic acetylcholine receptor subtypes 3, 4, and 5 as well as thyroid peroxid

83 Bombesin receptor subtype-3 (BRS-3) is an orphan G-protein-couple

84 This effect was mediated through PGE2 receptor subtype 4 (EP4) and an increase in intracellula

85 culata (SNr) act on muscarinic acetylcholine receptor subtype 4 (M4) to oppose cAMP-dependent dopamin

86 f the PTGER4 gene (encoding prostaglandin E2 receptor subtype 4; all P < 5 x 10(-5)).

87 Somatostatin receptor subtype-4 (SSTR4) agonists have been proposed t

88 osteric modulation of metabotropic glutamate receptor subtype 5 (mGlu(5)) is a promising novel approa

89 Metabotropic glutamate receptor subtype 5 (mGlu5) activators have emerged as a

90 ric modulators of the metabotropic glutamate receptor subtype 5 (mGlu5) have exciting potential as th

91 The metabotropic glutamate receptor subtype 5 (mGlu5) is a closely associated signa

92 Metabotropic glutamate receptor subtype 5 (mGluR5) is a potential drug target i

93 The metabotropic glutamatergic receptor subtype 5 (mGluR5) may represent a promising th

94 of GRM5, encoding the metabotropic glutamate receptor subtype 5 (mGluR5), which is coupled to the NMD

95 c radioligand for the metabotropic glutamate receptor subtype 5 (mGluR5).

96 equires interactions between GHS-R1a and SST receptor subtype 5 (SST5) and that in the absence of SST

97 Metabotropic glutamate receptor subtype 5 binding was quantified with positron

98 ketamine on brain metabotropic glutamatergic receptor subtype 5 with a high-affinity positron emissio

99 The serotonin receptor subtype 5-HT(1A) was one of the first serotonin

100 to advance the novel concept that serotonin receptor subtype 5-HT2C contributes critically to the im

101 the basolateral nucleus (BLA) and serotonin receptor subtype 5-HT2CR in the BLA, but not CeA, has be

102 modulator of the metabotropic glutamatergic receptor subtype 5.

103 with high binding affinity for somatostatin-receptor subtype 5.

104 n part, to changes in metabotropic glutamate receptors-subtype 5 (mGluR5) in the nucleus accumbens, a

105 The metabotropic glutamate receptor subtype 7 (mGlu7) is an important presynaptic r

106 The purinergic receptor subtype 7 (P2X7R) represents a novel molecular

107 hese results and docking experiments in both receptor subtypes, a molecular explanation was provided

108 Stimulation of the adenosine receptor subtype A2B increases the gap junction coupling

109 Acting at a single metabotropic receptor subtype, ACh exerts two opposing actions in cor

110 Of the four EP receptor subtypes active in SC cells, EP1 and EP3 recept

111 The crystal structures of the two receptor subtypes, ADIPOR1 and ADIPOR2, show a similar o

112 cation and recognition, suggesting that this receptor subtype affects consolidation and/or retrieval

113 The effects depend on receptor subtypes, affinity, concentration level, and th

114 uate the impact of the A2A and A2B adenosine receptor subtype agonist 2-phenylaminoadenosine (2-PAA)

115 nsfected with cDNAs encoding three requisite receptor subtypes: alpha7-nAChR, alpha4beta2-nAChR, and

116 otently inhibits the nicotinic acetylcholine receptor subtype alpha9alpha10 (alpha9alpha10 nAChR) and

117 Triple transfections of the dopamine receptor subtype and Gbeta and Ggamma subunits, each lab

118 Collectively, our findings show that D1 receptor subtype and related signaling in mPFC excitator

119 Expressed adenosine receptor subtypes and connexin (Cx) isoforms were identi

120 teractions are seen for very closely related receptor subtypes and for varying drugs at a given bindi

121 s, often resulting in poor selectivity among receptor subtypes and restricted pharmacologic profiles.

122 s also emphasize the importance of 5-HT2A/1A receptor subtypes and the Asp system in the control of s

123 Distinct effects are dependent on receptor subtypes and their differential expression.

124 he dynamic interactions between the dopamine receptor subtypes and their G-proteins using two-color f

125 y difficult because of the diversity of skin receptor subtypes and their location within the dermis a

126 o either greater sequence divergence between receptor subtypes and/or subtype-selective cooperativity

127 ne (NECA) (10 muM; agonist for all adenosine receptor subtypes) and CGS21680 (10 muM; selective A2A a

128 role for gliotransmission and the sites, P2 receptor subtype, and signalling mechanisms via which AT

129 alue of 233 nM, selectivity versus other P2Y receptor subtypes, and is thought to act as an allosteri

130 sion levels of different extrasynaptic GABAA receptor subtypes, and on the ambient GABA levels.

131 affinity for D4, relative to other dopamine receptor subtypes, and that this activity might underlie

132 ript focuses on SCI, these two innate immune receptor subtypes are also involved in developmental pro

133 Multiple 5-HT receptor subtypes are expressed in the CA3 region of the

134 The seven P2X receptor subtypes are implicated in physiological proces

135 iGluRs (AMPA, kainate, and NMDA receptor subtypes) are tetrameric assemblies, formed as

136 ndiscriminate activation of other muscarinic receptor subtypes, are common.

137 The present study points to these receptor subtypes as potential targets for the symptomat

138 ion appeared to be mediated via the RAR-beta receptor subtype, as ATRA remarkably induced RAR-beta mR

139 obility, and ultimately the function of NMDA receptor subtypes at synapses.

140 To make a quantitative estimate of NMDA receptor subtypes at wild-type synapses, we used the dea

141 show that mutation in the alpha2 -adrenergic receptor subtype B (alpha2B -AR) is associated with ADCM

142 Bruchpilot (BRP) and postsynaptic Glutamate receptor subtype B (GLURIIB), but no detectable change i

143 n is regulated by tropomyosin-related kinase receptor subtype B (TrkB) signaling in various neuronal

144 ferentiate between subpopulations of a given receptor subtype based on the receptor's dimerization st

145 otein, which requires activation of estrogen receptor subtype beta (ER-beta).

146 were not only dependent upon the particular receptor subtype but also whether it was a pyramidal cel

147 dimer interfaces of ORs across the different receptor subtypes, but also important differences in the

148 P2X receptor subtypes can be distinguished by their sensitiv

149 n, and that activation of all four histamine receptor subtypes can increase [Ca(2+)](i).

150 ific modulatory effects, we investigated the receptor subtypes, cell types and cellular mechanisms en

151 framework for the interpretation of observed receptor subtype combinations and possible assembly path

152 ted clinical efficacy as multiple Gq-coupled receptor subtypes contribute to these pathologies.

153 a(2+) signaling pathway linked to the VEGFR2 receptor subtype, controlling the critical angiogenic re

154 Thus, through distinct receptor subtypes coupled with different K(+) channels,

155 endogenous peptide urocortin1 (Ucn1) and two receptor subtypes, CRF-R1 and CRF-R2, in primary human a

156 Although CRF is known to activate two receptor subtypes, CRF1 and CRF2, attempts to delineate

157 ated activities at two off-targets: dopamine receptor subtype D2 and endocannabinoid receptor CB1.

158 tty acid amide hydrolase (FAAH) and dopamine receptor subtype D3 (D3R).

159 owed preferences for particular melanocortin receptor subtypes depending on the linker that connected

160 g how structural differences among glutamate receptor subtypes determine their distinct functional pr

161 s and provides insights into how cannabinoid receptor subtypes diversify the roles of cannabinoids in

162 The melanocortin system consists of five receptor subtypes, endogenous agonists, and naturally oc

163 elective antagonist for the prostaglandin E2 receptor subtype EP2, TG6-10-1, with a sufficient pharma

164 the potential that members of the muscarinic receptor subtype family hold as therapeutic drug targets

165 1) analyze the specificity of the histamine receptor subtypes for different heterotrimeric G-protein

166 ssible the selective blockade of vasopressin receptor subtypes for therapeutic purposes.

167 form functional heteromers with the galanin receptor subtype Gal1 (Gal1R), which modulate the activi

168 tive heteromerization of MOR and the galanin receptor subtype Gal1 (Gal1R).

169 ts unique pharmacological profile among NMDA receptor subtypes (GluN1/2A-D), in which DCS is a supera

170 GnRH receptor subtypes GnRHR1 and GnRHR2 were expressed in ch

171 ts on cholangiocytes by interaction with the receptor subtype (GnRHR1) expressed by cholangiocytes an

172 The four histamine receptor subtypes (H1R, H2R, H3R, and H4R) respond to th

173 ever, the mode of action of nicotine on this receptor subtype has been incompletely investigated.

174 This receptor subtype has long been object of intense researc

175 ficacious drugs that selectively target 5-HT receptor subtypes has been only occasionally successful.

176 harmacological differences between these two receptor subtypes have been described in heterologous ex

177 Although three TA receptor subtypes have been identified (TAR1-3), specifi

178 In particular, the M1 and M4 receptor subtypes have emerged as attractive drug target

179 3) and worst when they expressed none of the receptors (subtype HR0).

180 ere best when tumors expressed all 3 hormone receptors (subtype HR3) and worst when they expressed no

181 of Fgf2 KO mice, suggesting a role for other receptor subtypes (i.e., FGFR5).

182 Compounds that can act on GABAA receptor subtype in a selective manner, without the side

183 ce, here we identified a role of dopamine D1 receptor subtype in mPFC excitatory neurons in suppressi

184 stress (R-SDS) reduces the expression of D1 receptor subtype in mPFC of mice susceptible to R-SDS.

185 However, isolating specific receptor subtype in recombinant systems can be problemat

186 opening the possibility of drugs targeting a receptor subtype in specific brain regions.

187 atter thickness and BPnd for either dopamine receptor subtype in the control group.

188 ceptor (GPCR) and the predominant adrenergic receptor subtype in the heart, where it mediates cardiac

189 Knockdown of D1 receptor subtype in whole neuronal populations or excita

190 Similarly, AT-1001 desensitized both receptor subtypes in a concentration-dependent manner, b

191 dual differences in the activity of specific receptor subtypes in hotspot processes proposed by the G

192 , and the relative contribution of glutamate receptor subtypes in the CN were significantly altered.

193 et functional synaptic localization of these receptor subtypes in the dorsal horn has not been fully

194 CRF acts on both CRF1 and CRF2 receptor subtypes in the DRN that exert opposing inhibit

195 trated the involvement of dopamine D4 and D2 receptor subtypes in the effects of pramipexole.

196 thyl-4-isoxazole propionic acid) and kainate receptor subtypes in their major functional states and a

197 t with binding of benzodiazepines by a GABAA receptor-subtype in control of REM sleep.

198 gical as well as functional screening of P2Y receptor subtypes indicates the predominant involvement

199 uits affected by this system and the precise receptor subtypes involved in this modulation have not b

200 e nature of the immune subsets and adenosine receptor subtypes involved in this process are largely u

201 Identifying which receptor subtype is involved could facilitate treatment

202 This GABAA receptor subtype is thought to mediate sedation.

203 e other three benzodiazepine-sensitive GABAA receptor subtypes, is self-administered, and that the al

204 For some receptor subtypes it has been difficult to separate ther

205 These include: identification of the primary receptor subtype; its location on endothelial (EC) or va

206 determine contributions of the three D2-like receptor subtypes, knockout (KO) mice completely lacking

207 azine, already identified as selective GABAA receptor subtype ligands endowed with anxiolytic-like an

208 Continuing our research on GABAA receptor subtype ligands, here is reported the synthesis

209 d rapidly reversible optical control of NMDA receptor subtypes, LiGluNs should help unravel the contr

210 ose dependently acting on distinct mu-opioid receptor subtypes located at different levels of the neu

211 ing in neuropathic pain through a second LPA receptor subtype, LPA(5), involving a mechanistically di

212 vates erythropoiesis by activating the LPA 3 receptor subtype (LPA3) under erythropoietin (EPO) induc

213 We found that the muscarinic acetylcholine receptor subtype M3 (M3R) interacted directly with NOSTR

214 olinergic interneurons (ChIs) and muscarinic receptor subtypes (mAChRs) in the occurrence of a wide r

215 The existence of approximately 14 mammalian receptor subtypes, many of which possess similar pharmac

216 onist activity and that variation among NMDA receptor subtypes may be achieved by probing this region

217 Thus, both receptor subtypes may contribute to methamphetamine-indu

218 6beta2* nAChRs and that antagonists of these receptor subtypes may exhibit therapeutic potential.

219 icate that the D2R is the primary DA D2-like receptor subtype mediating the reinforcing effectiveness

220 Here we tested the hypothesis that the key receptor subtype mediating this effect is the D5 recepto

221 ocalization in the PnO of the specific GABAA receptor-subtypes mediating the REM sleep effects.

222 t that a breakdown of metabotropic glutamate receptor subtype mGluR5 and endocannabinoid signaling in

223 wever, it is unclear whether D2, D3, or both receptor subtypes modulate precise signals of feedback a

224 at also includes mu, delta, and kappa opioid receptor subtypes (MOR, DOR, and KOR, respectively).

225 ligands binding to the three classic opioid receptor subtypes, mu, kappa and delta, have high affini

226 OX2 receptors; a selective inhibitor of this receptor subtype, N-ethyl-2-[(6-methoxy-3-pyridinyl)[(2-

227 isruptions in N-methyl-D-aspartate glutamate receptor subtype (NMDAR)-mediated excitatory synaptic si

228 of the M1 receptor dimer population, but the receptor subtype non-selective antagonists atropine and

229 studies neither isolated a role of dopamine receptor subtype nor identified the site of its action i

230 rinic m2 receptor is the major acetylcholine receptor subtype of motoneurons; therefore, we analyzed

231 th clinical outcomes of p53 and ER (estrogen receptor) subtypes of breast cancer, while also predicti

232 d PKC selectively phosphorylates the Robo3.1 receptor subtype on serine 1330.

233 Of the eight metabotropic glutamate (mGlu) receptor subtypes, only mGlu7 is expressed presynaptical

234 In the NMDA receptor subtype, opening of the ion channel pore, media

235 t therapeutics targeting a specific estrogen receptor subtype or its downstream signaling would likel

236 type 5-HT(1A) was one of the first serotonin receptor subtypes pharmacologically characterized.

237 pes of mPFC neurons express several dopamine receptor subtypes, previous studies neither isolated a r

238 d parallels the expression pattern of the Y1 receptor subtype previously described by our group, as i

239 ishing the specific properties of individual receptor subtypes remains a major goal in the field of n

240 The pharmacological activation of LPA receptor subtypes represent a novel strategies for augme

241 ty to potentiate with a variety of glutamate receptor subtypes, requiring a fundamental change in our

242 ties for the dopamine D2 and serotonin 5-HT6 receptor subtype, respectively.

243 tenuation were mediated by CRF-R1 and CRF-R2 receptor subtypes, respectively, localized to presynapti

244 with the receptor fields of DD2R and DopR DA receptor subtypes, respectively.

245 study attempted to identify the adiponectin receptor subtype responsible for adiponectin's vascular

246 However, the known repertoire of P2 receptor subtypes responsible for the proinflammatory ef

247 models of psychosis, although the particular receptor subtype(s) responsible for such activity was un

248 thylated analogues of the NMDA and AMPA iGlu receptor subtype selective antagonists ArgTX-93 and ArgT

249 Using novel mGlu receptor subtype-selective allosteric modulators along w

250 thousands of ligands are known, but few are receptor subtype-selective and nearly all are cationic i

251 P2X receptor subtype-selective antagonists are promising can

252 r pharmacology and discusses two recent 5-HT receptor subtype-selective drugs, lorcaserin and pimavan

253 lators are an attractive approach to achieve receptor subtype-selective targeting of G protein-couple

254 ith new physical properties, chemotypes, and receptor subtype selectivities.

255 Here, we examine the GABAA receptor subtype selectivity of the weak partial agonist

256 tentiation of natural signaling, and that of receptor subtype selectivity.

257 tors has provided breakthroughs in obtaining receptor subtype-selectivity that can reduce the overall

258 This activity-dependent process is receptor subtype specific: GABAC receptors are maintaine

259 t recognizes SSTR, we found that distinctive receptor subtype-specific destinations correlated with o

260 ructions of On-Off DSGCs showed a GABAergic, receptor subtype-specific input field for generating dir

261 s.Hypothesizing that 5-HT may have cell- and receptor subtype-specific modulatory effects, we investi

262 The effects are determined by receptor subtype specificity, concentration level, and t

263 macrine cells and M1 ipRGCs express the SRIF receptor subtypes sst(2A) and sst4 respectively.

264 nctionally interchangeable and that multiple receptor subtypes subserving inhibition may offer divers

265 Moreover, the similar contribution of both receptor subtypes suggests the importance of a relative

266 educed agonist activity across all nicotinic receptor subtypes tested.

267 >55 nM were found for all other human-cloned receptor subtypes tested.

268 s of ethanol inhibit activity of a nicotinic receptor subtype that is expressed in brain areas associ

269 tulated that activation of the specific mGlu receptor subtype that mediates this response could inhib

270 pi, theta, rho1-3) can give rise to multiple receptor subtypes that are the site of action of many cl

271 e both biased agonism and the many mu opioid receptor subtypes that have been cloned.

272 e stability and synaptic accumulation of the receptor subtypes that mediate these distinct forms of i

273 ted radioiodinated ligands selective for CCK receptor subtypes that utilize the same allosteric ligan

274 e hippocampus, the major somatostatin (SRIF) receptor subtype, the sst2A receptor, is localized at po

275 regarding traffic exposure and tumor hormone receptor subtype, the traffic-breast cancer association

276 Among the different existing receptor subtypes, the homomeric alpha7 nAChR has attrac

277 and desensitized states of AMPA and kainate receptor subtypes, the ion channels are closed, whereas

278 Of the five muscarinic receptor subtypes, the M5 receptor is the only one detec

279 uropeptides acting through a broad number of receptor subtypes, the NPY family of receptors.

280 contrasting signaling profiles, of adenosine receptor subtypes, these compounds might have therapeuti

281 minating between beta2- and beta3-containing receptor subtypes, Thio-THIP could be a valuable tool in

282 s show high affinity for all five muscarinic receptor subtypes, thus increasing the likelihood of unw

283 erized the response of the human alpha3beta4 receptor subtype to nicotine and the mechanism of action

284 However, the contribution of GABAA receptor subtypes to anxiolysis is still controversial.

285 as simple as the flip-flop of glutamatergic receptor subtypes triggered by an "unusual" type of NMDA

286 te in both sexes, but that distinct estrogen receptor subtypes underlie each aspect of potentiation i

287 The expression of EP receptor subtypes was determined by RT-PCR.

288 he selectivity of NPA derivatives among NMDA receptor subtypes was mapped structurally to the ligand-

289 fibroblasts, which mainly expressed the S1P2 receptor subtype, we showed that FTY720-P selectively ac

290 ective pharmacological antagonists of opioid receptor subtypes, we reveal that endogenous mu-opioid r

291 ed cues, but the effects of blocking the two receptor subtypes were dissociable.

292 tro affinities of AMC20: toward dopaminergic receptor subtypes were measured in membrane homogenates

293 cacy and off-target binding at selected 5-HT receptor subtypes, where significant overlap in SAR with

294 ood since the same molecule can activate one receptor subtype while blocking another closely related

295 te excellent selectivity over the other mGlu receptor subtypes, while addition of larger C4-substitue

296 fully identify novel scaffolds of individual receptor subtypes with greater efficacy than isolated sc

297 that combined segments from NMDA and kainate receptors, subtypes with distinct pharmacological profil

298 ne acted as a potent agonist for all D2-like receptor subtypes, with the general rank order of potenc

299 the endogenous influence of specific opioid receptor subtypes within distinct brain regions remains

300 to 467-fold) toward MC4R over MC3R and MC5R receptor subtypes without compromising agonist potency.